This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT02018861
Previous Study | Return to List | Next Study

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation
ClinicalTrials.gov Identifier:
NCT02018861
First received: December 5, 2013
Last updated: May 16, 2017
Last verified: May 2017
  Purpose
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB050465, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. INCB050465 inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.

Condition Intervention Phase
B-Cell Malignancies Drug: INCB050465 Drug: itacitinib Drug: Rituximab Drug: Ifosfamide Drug: Carboplatin Drug: Etoposide Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Safety and tolerability assessed by summary of Adverse Events (AEs), clinical lab assessments, physical exam results, and 12-lead ECGs for INCB050465 as monotherapy and as a combination therapy [ Time Frame: Measured every 3 weeks for approximately 15 months ]

Secondary Outcome Measures:
  • Efficacy as measured by overall response rate [ Time Frame: Measured every 9 weeks for approximately 15 months ]
  • Pharmacokinetic collections to determine Cmax, Tmax, Cmin, half-life [ Time Frame: Measured for each patient at Day 1, Day 8, and Day 15 ]

Enrollment: 87
Study Start Date: March 2015
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INCB050465
escalating doses given every day (QD)
Drug: INCB050465
Experimental: INCB050465 in combination with itacitinib (INCB039110)
Starting dose of INCB050465 determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
Drug: INCB050465 Drug: itacitinib
Other Names:
  • INCB039110
  • itacitinib (INCB039110)
Experimental: INCB050465 rituximab, ifosfamide, carboplatin, and etoposide
Starting dose of INCB050465 determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
Drug: INCB050465 Drug: Rituximab Drug: Ifosfamide Drug: Carboplatin Drug: Etoposide

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 years or older, with lymphoid malignancies of B-cell origin including:

    1. Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)

      • EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma
      • INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologies
    2. Hodgkin's lymphoma (HL)
  • Life expectancy of 12 weeks or longer
  • Subject must have received ≥ 1 prior treatment regimen(s)
  • The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice

Exclusion Criteria:

  • Has history of brain metastasis, spinal cord compression (unless treated, asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or lymphoma involving the central nervous system (CNS)
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during dose escalation)
  • Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant
  • Received autologous hematopoietic stem cell transplant within the last 3 months
  • Inadequate marrow reserve assessed by hematologic laboratory parameters
  • Inadequate renal or liver function
  • Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02018861

Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Tucson, Arizona, United States
United States, Florida
Port Saint Lucie, Florida, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Michigan
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New York
New York, New York, United States
United States, Ohio
Cleveland, Ohio, United States
United States, South Carolina
Greenville, South Carolina, United States
United States, Tennessee
Knoxville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
Sponsors and Collaborators
Incyte Corporation
Investigators
Study Director: Fitzroy Dawkins, M.D. Incyte Corporation
  More Information

Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT02018861     History of Changes
Other Study ID Numbers: INCB 50465-101 (CITADEL-101)
Study First Received: December 5, 2013
Last Updated: May 16, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Neoplasms
Etoposide phosphate
Isophosphamide mustard
Carboplatin
Rituximab
Etoposide
Ifosfamide
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents

ClinicalTrials.gov processed this record on September 19, 2017